Damora Therapeutics
DMRA
Damora Therapeutics (DMRA) news
Recent news
Damora Therapeutics Inc (pre-reincorporation): Jefferies initiates coverage with buy rating; price target $50
AInvest Wire · Jul 27, 2026Damora Therapeutics Inc: H.C. Wainwright initiates coverage with buy rating; price target $45
AInvest Wire · Jun 11, 2026Damora Therapeutics Inc <DMRA.O>: TD Cowen initiates coverage with buy rating
TD Cowen has initiated coverage on Damora Therapeutics Inc (NASDAQ:DMRA), assigning the stock a "Buy" rating . This move aligns with a broader trend of increased analyst attention on the clinical-stage biotechnology firm, which has attracted multiple "Buy" ratings from other major firms in recent…
AInvest Wire · Jun 8, 2026Damora Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4)
AInvest Wire · Jun 1, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.